The Asia-Pacific hospital-acquired infection diagnostics market accounted for $418.937 million in 2019, and is expected to reach $780.882 million by 2027, registering a CAGR of 7.5% from 2020 to 2027.
Hospital-acquired infections (HAIs) are type of infections acquired during hospitalization and are commonly known as nosocomial infection. These infections can be acquired in hospital, nursing home, rehabilitation facility, outpatient clinic, or other clinical settings. They can be acquired from an infected patient, outside environment, or from a staff of that facility. The hospital-acquired infection diagnostics market is primarily driven by the growth in awareness among healthcare workers and proposed government initiatives by many governmental organizations. Further, in the developing economies such as China, India, and Brazil, the cleanliness and hygiene is minimum. Hence, it results in more hospital-acquired infections, which further increases the demand for hospital-acquired infection diagnostics. However, the increase in healthcare cost and prevalence of antibiotic resistant infections impede the market growth.
A majority of hospitals in APAC (approx. 70%) expect pharma and medical device manufacturers to maintain or increase on-site presence and support for new product training, but decrease their presence and support for sales detailing and service support. Moreover, in regions severely affected by COVID-19, vascular procedures have been reduced to life or limb salvaging cases, owing to new government directives or hospital guidelines. This measure is expected to keep hospital beds and healthcare providers available for COVID-19 patients, as well as to save personal protective equipment (PPE) and reduce viral transfer among patients and between patients and staff. All these factors are anticipated to impact the Asia-Pacific hospital-acquired infection diagnostics market as well in the future.
An increase in the number of hospital-acquired infections, especially in the developing and underdeveloped economies has surged the demand in the hospital-acquired control market. Different emerging economies such as India, China, South Africa, Brazil, and Mexico are witnessing a surge in the number of under-served patients. Economic development in these regions is creating scopes of the growth for the manufacturers on the back of a large patient pool. Growth in medical expenditure and infrastructure encouraged by the governments of the respective economies is enhancing the adoption rate of sophisticated medical devices, generating substantial revenue in the market. High demand for devices such as endoscope reprocessing devices which are capable of disinfecting medical devices is pushing ahead the boundaries of growth of the hospital-acquired infection diagnostics market. Innovations focused on avoiding cross contaminations and enhancing the patients' safety are gaining preference in the medical sector
Increase in investment in infectious disease-related researches propels the market growth. As an instance, as per the estimation of NHS in 2019, it states that NHS would invest more than USD 6 Billion on infectious disease-related research. Under such investments re-emerging diseases like tuberculosis and emerging infectious diseases like the Heartland and Bourbon viruses are taken into consideration. Increase in the number of healthcare-associated infection foster the market demand. Furthermore, it is particularly relevant for highly populated and developing regions. The growing emphasis on addressing the issue of tropical disease treatment and diagnosis in developing nations, United Nations Development Program (UNDP), World Health Organization (WHO), and United Nations Children’s Fund (UNICEF) have come up with TDR, the special program for research and training in tropical disease. The development of such special programs by various healthcare agencies is also opening new avenues for the application of various diagnostics methods supporting the growth of the market.
Rise in prevalence of population suffering from respiratory diseases, gastrointestinal infection, blood infection and others is expected to positively affect the growth of the market. Moreover, increase in initiatives undertaken by authorities and governments to improve healthcare systems and spread awareness regarding benefits of sanitization and personal hygiene are also expected to increase growth of the hospital-acquired infection diagnostics market. For instance, WHO had introduced an awareness program known as Patient Safety Solutions, in which WHO promoted hand hygiene adherence as a health care facility on priority to reduce the burden of infectious diseases. Thus, due to the introduction of various awareness programs, it is expected to create awareness among individuals regarding the hospital acquired infection, which would further create lucrative opportunities for key market vendors.
By Test Type
Molecular Diagnostics is projected as one of the most lucrative segment.
Asia Pacific Hospital-acquired Infection Diagnostics Market Segmentation
The Asia Pacific hospital-acquired infection diagnostics market is segmented based on product, test type, infection type, end user, and region. Based on product this market is segmented into instrument and reagents & consumables. Based on test type, the market is classified into molecular diagnostics, urinalysis, and immunoassay. Further, based on infection type, it is classified into hospital acquired pneumonia, bloodstream infections, surgical site infections, gastrointestinal Infections, urinary tract infections (UTI), and others. Based on end user this market is segmented into hospital, clinics, and others. Country wise, the market is analyzed across India, Nepal, Bhutan, Bangladesh, Maldives, Sri Lanka, Myanmar, and Rest of Asia-Pacific.
Segment review
On the basis of products, the reagent and consumables segment is estimated to garner largest share during the forecast period. This segment is expected to maintain its dominant position throughout the forecast period. Growth of the segment is attributed to rise in the number of patients suffering from various infectious diseases and high prevalence of hospital acquired infections in low and middle income countries. In addition, by infection type, the surgical site infections segment is estimated to garner largest share during the forecast period. This attributed to the low awareness regarding HAIs among healthcare workers and rise in number of surgeries, are expected to increase its adoption rate in the future.
By Infection Type
Surgical Site Infections is projected as one of the most lucrative segment.
By end user, the hospitals segment accounted for majority of the market share in 2019, and is anticipated to continue this trend throughout the forecast period, owing to rise in number of surgeries performed and high adoption rate of diagnostic instruments in hospitals and rise in number of patients diagnosed with infectious diseases and the high probability of infections in hospital premises through blood-borne or respiratory pathogen transmission are also anticipated to boost the market growth.
The key players operating in the Asia-Pacific hospital-acquired infection diagnostics market include BECTON, DICKINSON AND COMPANY, Cepheid, Abbott Laboratories, F. Hoffmann-LA Roche Ltd, AstraZeneca, Daiichi Sankyo Co., Ltd., Hologic, Inc., Siemens, BIOMERIEUX SA, NG Biotech.
By Country
India country would exhibit the highest CAGR of 8.5% during 2020-2027.
Key Benefits For Stakeholders
- The study provides an in-depth analysis of the hospital-acquired infection diagnostics market along with current trends and future estimations to elucidate the imminent investment pockets.
- It offers a quantitative analysis from 2019 to 2027, which is expected to enable stakeholders to capitalize on prevailing market opportunities.
- The key market players and their strategies have been analyzed to understand the competitive outlook of the market.
Asia-Pacific Hospital-Acquired Infection Diagnostics Market Report Highlights
| Aspects | Details |
 By Product |
|
 By Test Type |
|
 By Infection Type |
|
 By End User |
|
 By Country |
|
 Key Market Players | SIEMENS, NG BIOTECH, BECTON, DICKINSON AND COMPANY, ABBOTT LABORATORIES, CEPHEID, HOLOGIC, INC., BIOMERIEUX SA, DAIICHI SANKYO CO., LTD., F. HOFFMANN-LA ROCHE LTD., ASTRAZENECA |
Analyst Review
According to the analyst’s, the hospital-acquired infection diagnostics market is expected to witness a steady growth rate during the forecast period. The large-scale use of disinfectors and medical nonwovens in the healthcare industry, rise in emphasis on infection control policies within hospital premises, surge in geriatric population, and increase in number of surgeries performed across the Asia-Pacific region are expected to propel the growth of this market. However, the increase in healthcare cost and prevalence of antibiotic resistant infections impedes the market growth.
Rise in incidences of chronic disease, lung diseases, growth in aging population, and increase in ICU admission are some of the factors that majorly drive the market growth.
According to the perspectives of analyst’s, the hospital-acquired infection diagnostics market is dominated by well-established players; hence there is intense competition in the Asia Pacific market. There is a high adoption of these devices owing to increase in prevalence of infectious diseases, which propels the market growth. In addition, technological advancements is prevalent in the market thus, there is an increase in product launches, due to which the market is estimated to grow with a high CAGR. India and Bangladesh are expected to offer lucrative growth opportunities to the key players in the industry.
The total market value of Asia Pacific Hospital Acquired Infection Diagnostics Market is $418.937 million in 2019.
The forecast period for Asia Pacific Hospital Acquired Infection Diagnostics Market is 2020 to 2027
The market value of Asia Pacific Hospital Acquired Infection Diagnostics Market in 2027 is $780.882 million.
The base year is 2019 in Asia Pacific Hospital Acquired Infection Diagnostics Market
Top companies such as Abbott Laboratories, F. Hoffmann-LA Roche Ltd., Siemens, Biomerieux SA, Becton, Dickinson And Company held a high market position in 2019. These key players held a high market postion owing to the strong geographical foothold in different regions.
In test type segment molecular diagnostics is the most influencing segment. Hence, increase in the prevalence of the infectious diseases, increase in awareness and acceptance of personalized medicines, and growth in the biomarker identification drive the growth of this market. In addition, increase in adoption of the molecular diagnostics in the emerging economies act as an opportunity for the market growth.
The major factor that fuels the growth of the global Asia Pacific Hospital Acquired Infection Diagnostics Market includes Increase in geriatric population and Development of technologically advanced diagnostic products, rise in geriatric population, and others. furthermore, Demand for hospital acquired infection diagnostics from middle and low-income countries. This leads to surge in demand for hospital acquired infection diagnostics product which contribute to the growth of the market.
India has the highest growth rate in the market which is growing due to the contribution of the emerging country. This is due to improvement in health awareness, development in healthcare infrastructure, and rise in number of hospitals & clinics equipped with advanced medical facilities.
A Hospital-acquired infection also known as a nosocomial infection, is an infection that is acquired in a hospital or other health care facility To emphasize both hospital and nonhospital settings, it is sometimes instead called a healthcare associated infection.
Hospital-acquired infections are caused by viral, bacterial, and fungal pathogens; the most common types are bloodstream infection (BSI), pneumonia (eg, ventilator-associated pneumonia [VAP]), urinary tract infection (UTI), and surgical site infection (SSI).
Loading Table Of Content...
